Kymeta Demonstrates LEO and GEO SATCOM Interoperability During Military Battle Lab Exercise
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today seamless interoperability between the Kymeta™ u8 terminal, Kepler Communications low earth orbit (LEO) satellites, and geostationary (GEO) SATCOM terminals at an annual military battle lab exercise focused on the integration of operations, intelligence, and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005039/en/
Kymeta demonstrates LEO and GEO interoperability with the u8 at technical demonstration. (Photo: Business Wire)
The u8 is the first and only terminal available today to demonstrate the automatic handover between a GEO SATCOM terminal and Kepler LEO constellation with high throughput for communications on the move (COTM) and on the pause (COTP). Today’s warfighters require access to command and control (C2) networks providing message traffic, email, VoIP, and VTCs as well as higher throughput networks for sending and receiving large amounts of data. The demonstration proved that access to C2 networks and high throughput communications is possible with a single integrated terminal, the u8.
“While today’s mobile forces operating in remote environments may have communication access through a traditional very small aperture terminal (VSAT) or legacy COTM terminals, they do not have access to the high-throughput LEO constellations,” said Rob Weitendorf, Vice President, Business Development, Kymeta. “The u8 provides the needed capacity and seamless connectivity between LEO and GEO satellites. We could not be more thrilled with the excitement our demo received from the Special Forces community at the event.”
Three stationary ground stations with GEO and LEO capabilities located in Inuvik, Canada, Redmond, WA, and Tuscon, AZ were combined with one mobile terminal at the demonstration Virginia Beach, VA. Each station had access to six Kepler LEO satellites and two GEO satellites. The change from GEO to LEO and linear to circular polarization was automated and accomplished via software only. Kymeta and Kepler’s experimentation was focused on providing high data rate point-to-point communications where data was transmitted from ground station to ground station without connection to the cloud, followed by GEO SATCOM for day-to-day operations.
Results exceeded expectations and demonstrated a significant increase in performance with lower latency, enhanced look angles, and speeds that are approaching 10X faster than earlier products with higher throughput and total data passed. Testing results included download speeds of 240 Mbps and upload speeds of 193 Mbps achieved with over 2 GB of data transferred during a single LEO pass. This capability has utility in polar regions where access to high-throughput communications is unavailable and mechanically-steered antennas struggle in low temperatures.
The demonstration further validates Kymeta’s ability to provide a LEO upgrade path for its u8 terminals and seamlessly leverage hybrid connectivity across multiple satellite constellations and ground LTE. Kymeta is the only flat-panel antenna (FPA) with electronic beam steering and no moving parts built for mobility and designed for the needs of military, public safety, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005039/en/
Contact information
Business Inquiries for Kymeta:
Brenda Kuhns
Director of Marketing
Kymeta Corporation
bhuhns@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Director of PR & Content
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom